Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daihan Pharmaceutical Co.,Ltd. (023910.KQ)
Seoul, KR
Operating from South Korea, Daihan Pharmaceutical Co.,Ltd. focuses on the development, manufacturing, and distribution of therapeutic medications. The company's diverse product portfolio features physician-prescribed drugs, over-the-counter (OTC) remedies, quasi-pharmaceuticals, and a variety of intravenous infusion solutions. Established in 1945, the firm's corporate headquarters are situated in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.29% | -2.38% | -7.93% | -11.44% | -9.64% | -7.13% | -5.82% | -6.32% | -23.82% | -13.73% | +612.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.2% Q1'26: +5.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-18.1% Q1'26: -8.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.8% Q1'26: +12.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.0% ★ Q1'26: +14.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.3% ★ Q1'26: +12.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
204.19B
est: 204.50B (-0.1%)
|
208.61B
est: 211.70B (-1.5%)
|
215.70B
215.70B – 215.70B
+1.9% YoY
|
222.50B
222.50B – 222.50B
+3.2% YoY
|
229.10B
229.10B – 229.10B
+3.0% YoY
|
235.50B
235.50B – 235.50B
+2.8% YoY
|
| EBITDA |
49.61B
est: 47.04B (+5.5%)
|
40.41B
est: 48.70B (-17.0%)
|
49.62B
49.62B – 49.62B
+1.9% YoY
|
51.18B
51.18B – 51.18B
+3.2% YoY
|
52.70B
52.70B – 52.70B
+3.0% YoY
|
54.17B
54.17B – 54.17B
+2.8% YoY
|
| EBIT |
42.33B
est: 37.20B (+13.8%)
|
31.19B
est: 38.51B (-19.0%)
|
39.24B
39.24B – 39.24B
+1.9% YoY
|
40.47B
40.47B – 40.47B
+3.2% YoY
|
41.68B
41.68B – 41.68B
+3.0% YoY
|
42.84B
42.84B – 42.84B
+2.8% YoY
|
| Net Income |
33.76B
est: 31.03B (+8.8%)
|
27.64B
est: 29.32B (-5.7%)
|
32.78B
32.78B – 32.78B
+11.8% YoY
|
34.19B
34.19B – 34.19B
+4.3% YoY
|
37.46B
37.46B – 37.46B
+9.6% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
13.07B
est: 17.14B (-23.7%)
|
33.64B
est: 17.74B (+89.6%)
|
18.08B
18.08B – 18.08B
+1.9% YoY
|
18.65B
18.65B – 18.65B
+3.2% YoY
|
19.20B
19.20B – 19.20B
+3.0% YoY
|
19.74B
19.74B – 19.74B
+2.8% YoY
|
| EPS |
5,741.00
est: 5,278.00 (+8.8%)
|
4,701.00
est: 4,987.00 (-5.7%)
|
5,575.00
5,575.00 – 5,575.00
+11.8% YoY
|
5,814.00
5,814.00 – 5,814.00
+4.3% YoY
|
6,371.00
6,371.00 – 6,371.00
+9.6% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 1/5 | 3/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sungyoung Lee | Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 023910.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
